Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 28, 2019; 25(32): 4764-4778
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4764
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4764
On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B
Xiu-Juan Chang, Yong-Ping Yang, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing 100853, China
Xiu-Juan Chang, Yan Chen, Zheng Dong, Wen-Lin Bai, Yin-Yin Li, Yong-Ping Yang, Department of Therapeutic Research for Liver Cancer, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
Chao Sun, Yong-Ping Yang, Peking University 302 Clinical Medical School, Beijing 100039, China
Xiao-Dong Li, Qi-Yu Jiang, Li-Jun Sun, Cui-Hong Zhang, Dong-Ping Xu, Department of Research for Clinical Medicine, the Fifth Medical center of Chinese PLA General Hospital, Beijing 100039, China
Zu-Jiang Yu, Zhi-Qin Li, Department of Infectious Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Xiao-Dong Wang, Yong-Ping Chen, Department of Infectious and Liver Diseases, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Da Chen, Qin Li, Fuzhou Infectious Diseases Hospital, Fuzhou 350025, Fujian Province, China
Wen-Juan Du, Medical Department Training Graduate Office, Chinese PLA General Hospital, Beijing 100853, China
Hao Liao, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
Author contributions: Yang YP, Li Q and Chen YP designed research; Chang XJ, Sun C, Chen Y, Li XD, Chen YP, Yu ZJ, Dong Z, Bai WL, Chen D, Wang XD, Li ZQ and Du WJ performed research; Liao H, Jiang QY, Li YY, Zhang CH and Xu DP contributed new reagents or analytic tools; Chang XJ, Sun C, Chen Y, Li XD, Yang YP and Sun LJ analyzed data; Yang YP, Li Q and Chang XJ wrote the paper; Yang YP, Li Q and Chen YP made critical revisions of manuscript.
Supported by Chinese Ministry of Science and Technology Grants the Major Science and Technology Special Project Fund Scheme , No. 2013ZX10005002 and Beijing the Special Clinical Application Research and Translational Grants, No. Z151100004015221 .
Institutional review board statement: This manuscript was approved by the institutional review board.
Clinical trial registration statement: The clinical trial have been registered (NCT01965418).
Informed consent statement: All patients signed informed consent statement.
Conflict-of-interest statement: Authors disclose no any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yong-Ping Yang, MD, PhD, Chief Doctor, Department of Therapeutic Research for Liver Cancer, the fifth Medical Center of Chinese PLA General Hospital, 100 Western 4th Ring Middle Road, Beijing 100039, China. yongpingyang@hotmail.com
Telephone: +86-10-63879193 Fax: +86-10-63879193
Received: March 6, 2019
Peer-review started: March 6, 2019
First decision: April 11, 2019
Revised: May 14, 2019
Accepted: May 31, 2019
Article in press: June 1, 2019
Published online: August 28, 2019
Peer-review started: March 6, 2019
First decision: April 11, 2019
Revised: May 14, 2019
Accepted: May 31, 2019
Article in press: June 1, 2019
Published online: August 28, 2019
Core Tip
Core tip: Hepatitis B core-related antigen (HBcrAg) is an excellent monitor of hepatic histological changes, especially in patients with chronic hepatitis B treated with nucleoside analogs. Baseline HBcrAg level and logarithmic reduction of HBcrAg at week 72 of treatment can predict and monitor the chance of achieving regression of liver fibrosis and histological improvement.